AnaptysBio Inc

NASDAQ:ANAB   12:13:58 PM EDT
25.85
+0.15 (+0.58%)
Products, Regulatory

AnaptysBio Announces Sale Of Zejula Royalties For Up To $45 Mln

Published: 09/12/2022 12:17 GMT
AnaptysBio Inc (ANAB) - Anaptysbio Announces Sale of Zejula Royalties for Up to $45 Million.
Anaptysbio Inc - Sold Its Royalty Interest on Future Global Net Sales of Zejula to a Wholly-owned Subsidiary of Dri Healthcare Trust for Up to $45 Million.
Anaptysbio Inc - Also Eligible to Receive a Further $10 Million From Dri Upon FDA Approval of Zejula for Treatment of Endometrial Cancer.